Diabetes

histology_top_1

We offer a variety of preclinical efficacy, POC and MOA studies in different animal models of both type I and type II diabetes. We have an excellent track record when it comes to working with difficult models like ZDF rats and db/db mice and have extensive knowledge of how to quantitate beta-cell mass and other histological-pathological endpoints of diabetes.

We offer:

Acute studies

OGTT in rats and mice

OGTT glucose - lean SPD rats

OGTT glucose - Gubra DIO rats

Acute OGTT in C57BI6/J mice

AUC OGTT in C57BI6/J mice


Chronic efficacy studies

We offer:

Longterm effects on glucose homeostasis in ZDF rats

Data demonstrating the efficacy of 8 weeks chronic treatment with the DPP-4i (linagliptin), SGLT-2i (dapagliflozin), GLP-1 (liraglutide) and SUR (glibenclamide) on OGTT insulin and glucose levels in male ZDF rats. See paper: Hansen HH et al, 2014.

OGTT Insulin

OGTT Glucose

Longterm effects on pancreatic markers

Gubra has characterized the longterm effect of GLP-1 analogs on blood glucose, beta cell mass and signs of pancreatitis. See paper: Vrang et al, 2012. Gubra is highly experienced with the assessments of beta cell dynamics in ZDF rats and db/db mice. These data are pivotal when assessing a direct or indirect effect of a given compound”:


Mode of Action studies

We offer:

Hyperinsulinaemic euglycaemic clamp

Glucose infusion rate during hyperinsulinaemic euglycaemic clamp in lean and male Gubra DIO rats. Data demonstrates a reduced insulin sensivity in Gubra DIO rats compared to lean animals, and improved insulin sensitivity following treatment with the thiazolidinedione Pioglitazone.


Glucose infusion rate

The male ZDF rat model

Thorough knowledge of the ZDF rat model is a must if you want to optimize your study design in accordance with drug type and mode of action. Take a look at our film on the subject to learn more about how this model can be used.

However, if you're looking to evaluate the potential proliferative effects of various interventions (pharmacological or non-pharmacological), our research has shown that the db/db mouse model is preferable. To learn more about how the db/db model can be used, see our paper on the subject.

The business value
of science Read

We know our results ultimately have to generate value for your company. That’s why we focus on the quality and completeness of the data we provide. We choose the methodology that will yield the most usable results for your company. Scientific research requires care, accuracy and precision. This is the delicate balance we walk. Pursuing methods with scientific merit to give you results that you can use, and that will ultimately generate value for your business.

Quality
assurance Read

At Gubra, we are committed to high quality deliverables. Through the strength of our quality systems and processes, from administration and study conduction to data management and reporting, we provide structured, professional and experienced services. All critical processes are governed by Standard Operating Procedures that along with quality control documentation are controlled by our Quality Assurance Group. Consistent training and evaluation processes throughout the organization ensure Gubras dynamic and evolving Quality Assurance System.

Why we
keep it simple Read

Just because it’s science, doesn’t mean the research has to be complicated. One of our mantras is the need to get clear, simple answers from research. It’s true, with limited time and resources and infinite pressure to produce results, it can be very tempting to get the most bang for your proverbial buck by trying to include as many endpoints in a study as possible. Yet, what often happens with this approach is that you get inconclusive results that require further investigation, taking more time and using more resources. By taking a straightforward approach to study design, we ensure our customers get clear answers they can use.